Compare Devon Energy Corp (DVN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs GSK plc — how do they compare? Devon Energy Corp trades at $48.26 (market cap $53.81B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Devon Energy Corp for 136 Days and GSK plc for 93 Days on average.
| DVN | GSK | |
|---|---|---|
Market Cap | $53.81B | $91.88B |
Volume | 11,556,740 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $52.07 | $61.18 |
52-Week Low | $31.74 | $43.24 |
Typical Hold Time | 136 Days | 93 Days |
Enterprise Value | $64.55B | $111.88B |
Dividend Yield | 2.62% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $48.69, up 1.69% today, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 10.63, net income margin of 16.67%, and positive cash flow trends. Recent news highlights activist investor pressure for strategic alternatives, including a potential sale, amid ongoing M&A interest from firms like BP.
The outlook is positive, driven by valuation discounts, earnings beats, and potential asset sales, but risks include oil price volatility and execution challenges. Analyst consensus is strongly bullish with a $62.53 price target, suggesting significant upside from current levels.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
